UTM Stock Chart & Stats
€55.00
-€4.50(-7.56%)
At close: 4:00 PM EDT
€55.00
-€4.50(-7.56%)
Day’s Range― - ―
52-Week Range€45.60 - €64.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€193.15M
Enterprise Value€132.27
Total Cash (Recent Filing)€87.41M
Total Debt (Recent Filing)€210.00K
Price to Earnings (P/E)22.0
Beta0.41
Next Earnings
Oct 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.30
Shares Outstanding3,184,025
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.18
Price to Book (P/B)1.55
Price to Sales (P/S)4.81
P/FCF Ratio12.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetUtah Medical's near-zero leverage and very small trailing debt provide durable financial flexibility. Low leverage reduces solvency risk during procedure-volume downturns, supports consistent capital allocation choices (operating investment, dividends or opportunistic M&A), and underpins resilience across a multi-month to multi-year horizon.
High Margins / Pricing PowerSustained high gross and net margins signal structural pricing strength and efficient cost control in device manufacturing. Higher margins allow the company to absorb reimbursement pressure or input cost swings, sustain attractive returns on capital, and fund reinvestment without immediate need for large revenue gains.
Recurring Consumable DemandA product mix centered on single-use disposables creates predictable reorder streams tied to routine clinical procedures. This recurring consumable model reduces revenue volatility versus pure capital-equipment firms, supports steady unit demand, and allows long-term planning for production and distribution across hospitals and distributor networks.
Bears Say
Sustained Revenue DeclineMulti-year top-line contraction is a persistent structural headwind: declining revenue erodes operating leverage, can compress future growth opportunities, and raises the bar for management to restore momentum. If demand in core obstetrics/gynecology and neonatal segments remains weak, recovery may require new product wins or market expansion.
Softening Free Cash FlowAlthough FCF still tracks earnings closely, a roughly 9% TTM decline in free cash flow reduces the company's cushion for discretionary investments, R&D, or increased shareholder returns. A sustained downward FCF trend would limit strategic flexibility and could force tougher trade-offs among reinvestment, dividends, and balance-sheet uses.
Small Scale / Concentration RiskA small employee base and tight clinical focus constrain scale, geographic reach, and diversification. Limited scale can weaken bargaining power with large hospital systems and increase sensitivity to procedure-volume swings or customer concentration, making sustained top-line growth and durable margin expansion more challenging.
Utah Medical Products News
UTM FAQ
What was Utah Medical Products’s price range in the past 12 months?
Utah Medical Products lowest stock price was €45.60 and its highest was €64.00 in the past 12 months.
What is Utah Medical Products’s market cap?
Utah Medical Products’s market cap is €193.15M.
When is Utah Medical Products’s upcoming earnings report date?
Utah Medical Products’s upcoming earnings report date is Oct 27, 2026 which is in 89 days.
How were Utah Medical Products’s earnings last quarter?
Utah Medical Products released its earnings results on Jul 23, 2026. The company reported €0.74 earnings per share for the quarter, beating the consensus estimate of N/A by €0.74.
Is Utah Medical Products overvalued?
According to Wall Street analysts Utah Medical Products’s price is currently Overvalued.
Does Utah Medical Products pay dividends?
Utah Medical Products does not currently pay dividends.
What is Utah Medical Products’s EPS estimate?
Utah Medical Products’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Utah Medical Products have?
Utah Medical Products has 3,184,025 shares outstanding.
What happened to Utah Medical Products’s price movement after its last earnings report?
Utah Medical Products reported an EPS of €0.74 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.709%.
Which hedge fund is a major shareholder of Utah Medical Products?
Currently, no hedge funds are holding shares in DE:UTM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Utah Medical Products Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.85%
12-Months-Change
Fundamentals
Return on Equity
1.77%
Trailing 12-Months
Asset Growth
3.12%
Trailing 12-Months
Company Description
Utah Medical Products
Utah Medical Products, Inc. (UTMD) is a healthcare technology company focused on the creation, production, and supply of medical devices for the healthcare sector. UTMD offers a comprehensive portfolio of medical devices primarily serving labor and delivery departments and neonatal intensive care units. Key offerings include fetal monitoring accessories, vacuum-assisted delivery systems, and other specialized tools for childbirth. For newborns, they provide respiratory hoods (DISPOSA-HOOD), umbilical vessel catheters (GESCO), silicone oral protection devices (PALA-NATE), and lumbar sampling kits (MYELO-NATE). Beyond maternity care, the company supplies blood pressure monitoring systems (DELTRAN PLUS), disposable peritoneal dialysis sets (DIALY-NATE), urinary drainage systems (URI-CATH), and feeding devices (NUTRI-CATH/NUTRI-LOK). They also manufacture HEMO-NATE disposable filters, various catheterization procedure trays, and DELTRAN disposable pressure transducers along with related accessories and molded parts. A substantial portion of UTMD's offerings targets women's health and gynecological interventions. This includes advanced electrosurgical solutions like the LETZ system for cervical lesion excision, paired with FINESSE+ generators and various specialized electrodes (loop, ball, needle), and FILTRESSE evacuators. They also provide laparoscopic instruments (Femcare line), including trocars and cannulae, alongside EPITOME and OptiMicro electrosurgical devices. Complementing these are products for surgical contraception (Filshie Clip), endoscopic irrigation (PATHFINDER PLUS), suprapubic catheterization, and urinary incontinence management (LIBERTY systems). Specialized tools for uterine assessment and sampling, such as the ENDOCURETTE and TVUS/HSG-Cath, as well as the LUMIN uterine manipulator for laparoscopic procedures, complete this extensive portfolio. UTMD's diverse product range serves various healthcare settings, including neonatal intensive care units, labor and delivery wards, women's health centers within hospitals, outpatient clinics, and physicians' offices. The company facilitates distribution through a combination of direct customer service and sales teams, independent consultants, and manufacturer representatives. Established in 1978, Utah Medical Products, Inc. maintains its headquarters in Midvale, Utah.